<DOC>
	<DOCNO>NCT01357889</DOCNO>
	<brief_summary>The first part study include single dose treatment period evaluate pharmacokinetic bioequivalence subcutaneous injection albiglutide process 2 drug substance compare process 3 drug substance . The second part treatment period evaluate additional pharmacokinetic pharmacodynamic parameter safety tolerability repeat dos albiglutide give weekly 12 week process 2 drug substance compare process 3 drug substance . Subjects type 2 diabetes whose glycemia inadequately control current regimen diet exercise stable dose metformin recruit study .</brief_summary>
	<brief_title>Pharmacokinetics/Pharmacodynamics Albiglutide</brief_title>
	<detailed_description>This randomize , double-blind , multicenter , 2 parallel group study . The first part treatment period evaluate pharmacokinetic bioequivalence single dose subcutaneous injection 30mg albiglutide process 2 drug substance compare process 3 drug substance . The second part treatment period evaluate additional pharmacokinetic parameter , pharmacodynamic parameter , immunogenicity , effect glycosylated hemoglobin fast plasma glucose , safety tolerability repeat dose subcutaneous injection 30mg albiglutide give weekly 12 week process 2 drug substance compare process 3 drug substance . Subjects type 2 diabetes whose glycemia inadequately control current regimen diet exercise stable dose metformin recruit study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Subjects historical diagnosis type 2 diabetes mellitus experience inadequate glycemic control current regimen diet exercise stable dose metformin Body mass index ≥20 kg/m2 ≤45 kg/m2 Fasting Cpeptide ≥0.8 ng/mL ( ≥0.26 nmol/L ) Thyroidstimulating hormone level normal clinically euthyroid Female subject childbearing potential ( i.e. , surgically sterile and/or postmenopausal ) must practice adequate contraception . Current ongoing symptomatic biliary disease history pancreatitis History significant GI surgery Recent clinically significant cardiovascular and/or cerebrovascular disease History human immunodeficiency virus infection History , current hepatic disease History alcohol substance abuse Female subject pregnant , lactating , &lt; 6 week postpartum History type 1 diabetes Receipt investigational drug within 30 day , 5 halflives whichever longer , Screening history receipt investigational antidiabetic drug within 3 month randomization , receipt GLP1 agent include albiglutide History , family history thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>GSK716155</keyword>
	<keyword>albiglutide</keyword>
</DOC>